Belite Bio (NASDAQ: BLTE) is a San Diego based clinical stage drug development company targeting untreatable eye diseases, such as dry AMD and Stargardt disease (STGD1) which is the most common inherited retinal dystrophy, and metabolic diseases. Its lead pipeline, Tinlarebant (aka LBS-008), is a novel oral once-a-day tablet intended to treat Dry AMD and STGD1 early. Tinlarebant is in phase 3 and has been granted Fast Track & RPD designation in the US, and ODD in the US and EMA for STGD1.
| Website | http://www.belitebio.com |
| Employees | 63 (42 on RocketReach) |
| Founded | 2018 |
| Address | 5820 Oberlin Drive Suite 101, San Diego, California 92121, US |
| Phone | +1 212-491-4107 |
| Technologies |
HTML
,
Google Analytics
,
reCAPTCHA
+9 more
(view full list)
|
| Industry | Biotechnology Research, Drug Discovery, Pharmaceuticals |
| Keywords | Ophthalmology, Ophthalmic Drugs, Macular Degeneration, Clinical Stage Biopharma, Drug Discovery, Vision Loss, Biotechnology, Rare Diseases, Gene Therapy, Clinical Trials, Pharmaceutical Research, Metabolic Disorders |
| Competitors | Novartis, Pfizer, Sanofi, AstraZeneca, Bristol Myers Squibb, Amgen, Regeneron, Gilead Sciences, Moderna Therapeutics, Lilly India +57 more (view full list) |
Looking for a particular Belite Bio employee's phone or email?
Irene Wang is the Co-Founder of Belite Bio.
42 people are employed at Belite Bio.
Belite Bio is based in San Diego, California.